AQST Aquestive Therapeutics, Inc.
Healthcare$4.12-2.60%ClosedMarket Cap: $409.1M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
-14.83
P/S
8.14
EV/EBITDA
-7.80
DCF Value
$-2.24
FCF Yield
-10.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.5%
Operating Margin
-111.2%
Net Margin
-137.1%
ROE
190.9%
ROA
-48.8%
ROIC
-44.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $14.4M | 76.0% | $-4.2M | $-8.1M | $— | — |
| Q4 null | $13.0M | 55.2% | $-28.8M | $-31.9M | $— | — |
| FY null | $44.5M | 61.5% | $-69.7M | $-83.8M | $— | — |
| Q3 null | $12.8M | 64.8% | $-11.5M | $-15.4M | $— | — |
| Q2 null | $10.0M | 54.4% | $-11.4M | $-13.5M | $— | — |
| Q1 null | $8.7M | 58.1% | $-19.4M | $-22.9M | $— | — |
| Q4 null | $11.9M | 61.9% | $-13.6M | $-17.1M | $— | — |
| FY null | $57.6M | 69.0% | $-30.8M | $-44.1M | $— | — |
| Q3 null | $13.5M | 67.2% | $-8.3M | $-11.5M | $— | — |
| Q2 null | $20.1M | 77.5% | $55.0K | $-2.7M | $— | — |
| Q1 null | $12.1M | 63.6% | $-9.0M | $-12.8M | $— | — |
| Q4 2023 | $13.2M | 64.6% | $-3.9M | $-8.1M | $-0.12 | — |